India, July 29 -- NeoGenomics, Inc. (NEO), a cancer diagnostics company, announced second-quarter results for the period ended June 30, 2026, reflecting 11% revenue growth. In addition, the company raised revenue guidance for the full year 2026.
NeoGenomics specialises in cancer genetics testing and information services and focuses on oncology-focused tests. It operates a network of cancer-focused testing laboratories and offers testing services to hospitals, academic centres, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.
Second Quarter Results
For the second quarter of 2026, the firm swung to net income of $2.24 million or $0.02 per share compared to a net loss of $45.09 million or $0.35 per...